MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication-Reference-Cited by-同舟云学术

MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ruiz Isaac¹²,Nevers Quentin¹,Hernández Eva¹,Ahnou Nazim¹³,Brillet Rozenn¹,Softic Laurent¹,Donati Flora¹³,Berry Francois¹,Hamadat Sabah¹³,Fourati Slim¹³^ORCID,Pawlotsky Jean-Michel¹³,Ahmed-Belkacem Abdelhakim¹^ORCID

Affiliation:

1. Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, Team “Viruses, Hepatology, Cancers”, Hôpital Henri Mondor, Université Paris-Est, Créteil, France

2. Department of Hepatology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France

3. National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France

Abstract

The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. While studying the modulatory effect of MRP-1 on anti-hepatitis C virus (HCV) direct-acting antiviral (DAA) efficiency, we observed an unexpected anti-HCV effect of compound MK-571 alone. This anti-HCV activity was characterized in Huh7.5 cells stably harboring a subgenomic genotype 1b replicon. A dose-dependent decrease of HCV RNA levels was observed upon MK-571 administration, with a 50% effective concentration (EC 50 ± standard deviation) of 9 ± 0.

Funder

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02078-19

Reference33 articles.

1. Hepatitis C Virus Infection

2. Replication of hepatitis C virus

3. WHO. 2017. Global hepatitis report 2017. WHO, Geneva, Switzerland.